Analysts expect that Repligen Co. (NASDAQ:RGEN) will report $41.37 million in sales for the current quarter, according to Zacks Investment Research. Four analysts have issued estimates for Repligen’s earnings. The lowest sales estimate is $40.90 million and the highest is $42.06 million. Repligen posted sales of $25.60 million during the same quarter last year, which would indicate a positive year over year growth rate of 61.6%. The firm is scheduled to issue its next earnings results on Wednesday, February 28th.

On average, analysts expect that Repligen will report full-year sales of $41.37 million for the current fiscal year, with estimates ranging from $140.50 million to $141.68 million. For the next fiscal year, analysts expect that the firm will post sales of $184.76 million per share, with estimates ranging from $181.63 million to $190.00 million. Zacks’ sales averages are an average based on a survey of sell-side analysts that that provide coverage for Repligen.

Repligen (NASDAQ:RGEN) last announced its quarterly earnings results on Thursday, November 9th. The biotechnology company reported $0.15 earnings per share for the quarter, topping the consensus estimate of $0.11 by $0.04. Repligen had a net margin of 16.93% and a return on equity of 7.57%. The firm had revenue of $36.58 million during the quarter, compared to analysts’ expectations of $35.69 million. During the same quarter in the prior year, the company earned $0.08 EPS. The company’s revenue was up 48.2% compared to the same quarter last year.

RGEN has been the subject of several research reports. TheStreet raised shares of Repligen from a “c+” rating to a “b-” rating in a research report on Friday, August 11th. Zacks Investment Research raised shares of Repligen from a “hold” rating to a “buy” rating and set a $43.00 price target for the company in a research report on Thursday, October 5th. CL King initiated coverage on shares of Repligen in a research report on Monday, November 13th. They issued a “buy” rating and a $41.00 price target for the company. BidaskClub raised shares of Repligen from a “hold” rating to a “buy” rating in a research report on Wednesday, August 9th. Finally, Jefferies Group reissued a “hold” rating and set a $40.00 target price on shares of Repligen in a research report on Thursday, September 14th. Two analysts have rated the stock with a hold rating and six have issued a buy rating to the company. The company has a consensus rating of “Buy” and an average target price of $44.29.

Shares of Repligen (NASDAQ:RGEN) opened at $35.10 on Wednesday. Repligen has a 52-week low of $28.48 and a 52-week high of $46.81. The firm has a market cap of $1,530.00, a P/E ratio of 61.22, a PEG ratio of 2.31 and a beta of 1.04.

A number of large investors have recently bought and sold shares of the stock. BlackRock Inc. raised its holdings in shares of Repligen by 3.7% in the second quarter. BlackRock Inc. now owns 4,834,853 shares of the biotechnology company’s stock worth $200,355,000 after buying an additional 170,551 shares during the last quarter. TimesSquare Capital Management LLC raised its holdings in shares of Repligen by 19.8% in the second quarter. TimesSquare Capital Management LLC now owns 2,361,270 shares of the biotechnology company’s stock worth $97,851,000 after buying an additional 390,545 shares during the last quarter. Vanguard Group Inc. raised its holdings in shares of Repligen by 9.7% in the second quarter. Vanguard Group Inc. now owns 1,984,393 shares of the biotechnology company’s stock worth $82,233,000 after buying an additional 175,191 shares during the last quarter. Conestoga Capital Advisors LLC raised its holdings in shares of Repligen by 12.5% in the third quarter. Conestoga Capital Advisors LLC now owns 1,453,232 shares of the biotechnology company’s stock worth $55,688,000 after buying an additional 161,427 shares during the last quarter. Finally, FMR LLC raised its holdings in shares of Repligen by 6.2% in the second quarter. FMR LLC now owns 1,334,090 shares of the biotechnology company’s stock worth $55,285,000 after buying an additional 78,060 shares during the last quarter. 83.31% of the stock is owned by institutional investors.

ILLEGAL ACTIVITY NOTICE: This piece was published by American Banking News and is owned by of American Banking News. If you are viewing this piece on another site, it was stolen and republished in violation of US & international copyright and trademark law. The original version of this piece can be read at https://www.americanbankingnews.com/2017/12/06/analysts-expect-repligen-co-rgen-will-post-quarterly-sales-of-41-37-million.html.

Repligen Company Profile

Repligen Corporation is a bioprocessing company. The Company is focused on the development, manufacture and commercialization of products used to improve the interconnected phases of the biological drug manufacturing process. The Company’s portfolio includes protein products, chromatography products, and filtration products.

Get a free copy of the Zacks research report on Repligen (RGEN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Repligen (NASDAQ:RGEN)

Receive News & Ratings for Repligen Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen Co. and related companies with MarketBeat.com's FREE daily email newsletter.